Factual side-by-side: what each tool does, where each is strong, and where each is thin. IQVIA is positioned as enterprise pharma market intelligence and clinical research. Distrolens is positioned as named distributor intelligence for 21 emerging markets (Nigeria, Saudi Arabia, UAE, Kenya, and 17 more), sourced from regulator registries.
IQVIA aggregates prescriber-level prescribing data, wholesaler audit panels, and retail dispensing data into MIDAS — the industry-standard market-share estimator for pharma manufacturers. Their CSMS Pipeline and OneKey reference data extend into HCP intelligence and clinical-trial site networks.
Pharma distribution intelligence: named distributors across 21 emerging markets, sourced from regulator registries (NAFDAC, SFDA, MOHAP, SAHPRA, EudraGMDP, TED). Verified contact emails, supply-chain edges, sanctions screening (14-day half-life), and live Chao1 coverage published per country including where we are weak.
5 dimensions. Claims are factual and citable — sourced from IQVIA’s own public materials and Distrolens production data. No marketing puffery either way.
Estimated market shares from prescriber + wholesaler panels — aggregated numbers, no distributor entities named
Named distributor companies with verified contact emails, supply-chain edges, regulator-source provenance
Developed-market focus — MIDAS panels are thin or absent in Nigeria, Kenya, Tanzania, Uganda, Vietnam, Egypt
21 emerging markets in scope, 8 with sales-ready depth (NG, ZA, UG, SA, VN, TZ, KE, AE)
Coverage methodology not published per country — panel thinness in emerging markets is an industry-known issue
Live Chao1 capture-recapture coverage published per country at /coverage, including where we are weak
$150K+/yr, 12-36 month enterprise contracts
$500/country/month List · $1,200/country/month Intel · month-to-month
Multi-week procurement, NDA, onboarding
20-min discovery call → CSV + REST API access within days
Six-figure annual contracts — $150K-300K/yr typical for MIDAS Market Access subscriptions
Contract: 12-36 month enterprise contracts, typically.
Source: Public pharma-industry analyst reports + IQVIA earnings (NYSE:IQV); exact pricing under NDA
$500/country/month List · $1,200/country/month Intel · bundle discounts −15% / −25% / −30% at 3 / 6 / 10+ countries.
Contract: month-to-month, no minimum, cancel any month.
20-minute discovery call required before CSV + REST API access.
You need market-share percentages for established markets (US/EU/Japan) and have six-figure budget. IQVIA is the industry standard for that exact use case.
You need named distributors in emerging markets with verified contact paths, and you'd rather pay 5-10× less for that specific outcome.